Structure Therapeutics (GPCR) Competitors $27.90 -2.07 (-6.91%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GPCR vs. MDGL, NUVL, LEGN, IONS, BPMC, ELAN, CYTK, CORT, TLX, and TGTXShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Madrigal Pharmaceuticals (MDGL), Nuvalent (NUVL), Legend Biotech (LEGN), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Corcept Therapeutics (CORT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical preparations" industry. Structure Therapeutics vs. Madrigal Pharmaceuticals Nuvalent Legend Biotech Ionis Pharmaceuticals Blueprint Medicines Elanco Animal Health Cytokinetics Corcept Therapeutics Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Madrigal Pharmaceuticals (NASDAQ:MDGL) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership. Is MDGL or GPCR more profitable? Structure Therapeutics' return on equity of -16.37% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Madrigal PharmaceuticalsN/A -71.78% -53.25% Structure Therapeutics N/A -16.37%-15.68% Do analysts prefer MDGL or GPCR? Madrigal Pharmaceuticals currently has a consensus price target of $347.33, indicating a potential upside of 12.61%. Structure Therapeutics has a consensus price target of $86.50, indicating a potential upside of 210.04%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Madrigal Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in MDGL or GPCR? 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, MDGL or GPCR? Madrigal Pharmaceuticals has a beta of -0.42, suggesting that its share price is 142% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -3.41, suggesting that its share price is 441% less volatile than the S&P 500. Which has higher valuation & earnings, MDGL or GPCR? Structure Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMadrigal Pharmaceuticals$76.81M87.58-$373.63M-$25.08-12.30Structure TherapeuticsN/AN/A-$89.62M-$0.74-37.70 Does the MarketBeat Community believe in MDGL or GPCR? Madrigal Pharmaceuticals received 428 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 87.88% of users gave Structure Therapeutics an outperform vote while only 67.70% of users gave Madrigal Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMadrigal PharmaceuticalsOutperform Votes45767.70% Underperform Votes21832.30% Structure TherapeuticsOutperform Votes2987.88% Underperform Votes412.12% Does the media prefer MDGL or GPCR? In the previous week, Structure Therapeutics had 11 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 18 mentions for Structure Therapeutics and 7 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.28 beat Structure Therapeutics' score of 0.71 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMadrigal Pharmaceuticals and Structure Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.60B$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-37.7010.5991.3417.19Price / SalesN/A195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book2.865.104.794.78Net Income-$89.62M$151.51M$120.07M$225.60M7 Day Performance-10.72%-2.15%-1.89%-1.24%1 Month Performance-7.31%-3.14%11.45%3.36%1 Year Performance-15.45%11.50%30.61%16.58% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.3698 of 5 stars$27.90-6.9%$86.50+210.0%-15.4%$1.60BN/A-37.70136Analyst ForecastNews CoverageGap UpHigh Trading VolumeMDGLMadrigal Pharmaceuticals4.2369 of 5 stars$310.20+1.9%$347.33+12.0%+39.5%$6.77BN/A-12.1490Positive NewsNUVLNuvalent2.1736 of 5 stars$86.65-0.2%$112.60+29.9%+16.9%$6.16BN/A-25.0340Insider TradeNews CoveragePositive NewsLEGNLegend Biotech1.553 of 5 stars$33.53-4.5%$81.54+143.2%-43.2%$6.12B$520.18M-36.971,800IONSIonis Pharmaceuticals4.4165 of 5 stars$38.43+5.0%$60.65+57.8%-26.3%$6.07B$803.07M-15.00800Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsBPMCBlueprint Medicines2.5942 of 5 stars$95.29+2.3%$122.11+28.1%+7.2%$6.05B$434.42M-45.28640Insider TradeELANElanco Animal Health3.7675 of 5 stars$12.19+0.7%$16.75+37.4%-17.0%$6.03B$4.45B30.259,300CYTKCytokinetics4.1299 of 5 stars$49.10+0.9%$83.93+70.9%+36.8%$5.79B$3.22M-9.04250Analyst ForecastCORTCorcept Therapeutics4.9101 of 5 stars$54.90-0.9%$65.25+18.9%+66.5%$5.75B$482.38M43.97300Analyst RevisionTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.68+5.8%$21.00+25.9%N/A$5.58BN/A0.00N/ANews CoveragePositive NewsTGTXTG Therapeutics4.3117 of 5 stars$34.56+7.9%$40.67+17.7%+87.1%$5.38B$233.66M-320.17290Positive News Related Companies and Tools Related Companies Madrigal Pharmaceuticals Alternatives Nuvalent Alternatives Legend Biotech Alternatives Ionis Pharmaceuticals Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Corcept Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GPCR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GPCR Stock Alerts